Have physiologically-based pharmacokinetic models delivered?

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Expert Opinion on Drug Metabolism & Toxicology

• Publication date

  2011-07-18

• Fields of study

  Medicine, Chemistry, Computer Science

• Identifiers
  DOI 10.1517/17425255.2011.585968PMID 21762039
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of modeling and simulation in pediatric investigation plans

  2011cited by this paper
• Physiologically-based pharmacokinetics in drug development and regulatory science.

  2011cited by this paper
• A hybrid approach to advancing quantitative prediction of tissue distribution of basic drugs in human.

  2011cited by this paper
• Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review

  2011influential reference
• Drug interactions evaluation: an integrated part of risk assessment of therapeutics.

  2010cited by this paper
• Risk Assessment in Extrapolation of Pharmacokinetics from Preclinical Data to Humans

  2010cited by this paper
• Physiologically based pharmacokinetic (PBPK) tool kit for environmental pollutants – metals

  2010cited by this paper
• A unified algorithm for predicting partition coefficients for PBPK modeling of drugs and environmental chemicals.

  2010cited by this paper
• Prediction of Phase I single-dose pharmacokinetics using recombinant cytochromes P450 and physiologically based modelling

  2009cited by this paper
• Exploratory population pharmacokinetics (e-PPK) analysis for predicting human PK using exploratory ADME data during early drug discovery research

  2009influential reference
• Physiologically-based Simulation Modelling for the Reduction of Animal Use in the Discovery of Novel Pharmaceuticals

  2009cited by this paper
• Proposals for model-based paediatric medicinal development within the current European Union regulatory framework.

  2009cited by this paper
• Modelling and PBPK Simulation in Drug Discovery

  2009cited by this paper
• Physiology-Based Simulations of a Pathological Condition

  2008cited by this paper
• Whole body physiologically-based pharmacokinetic models: their use in clinical drug development

  2008cited by this paper
• Drug–drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 2: clinical trial results

  2008cited by this paper
• Pharmacometrics: A Multidisciplinary Field to Facilitate Critical Thinking in Drug Development and Translational Research Settings

  2008cited by this paper
• Drug–drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDes

  2008cited by this paper
• Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man.

  2008cited by this paper
• Evaluation of a basic physiologically based pharmacokinetic model for simulating the first-time-in-animal study.

  2007cited by this paper
• Theoretical Biology and Medical Modelling Open Access Dynamically Simulating the Interaction of Midazolam and the Cyp3a4 Inhibitor Itraconazole Using Individual Coupled Whole-body Physiologically-based Pharmacokinetic (wb-pbpk) Models

  2007cited by this paper
• Challenges and opportunities with modelling and simulation in drug discovery and drug development

  2007cited by this paper
• Prediction of Human Pharmacokinetics Using Physiologically Based Modeling: A Retrospective Analysis of 26 Clinically Tested Drugs

  2007cited by this paper
• Comparison of different approaches to predict metabolic drug–drug interactions

  2007cited by this paper
• Perchlorate and Radioiodide Kinetics Across Life Stages in the Human: Using PBPK Models to Predict Dosimetry and Thyroid Inhibition and Sensitive Subpopulations Based on Developmental Stage

  2007cited by this paper
• Whole-body physiologically based pharmacokinetic models

  2007cited by this paper
• Characterizing uncertainty and variability in physiologically based pharmacokinetic models: state of the science and needs for research and implementation.

  2007cited by this paper
• Simulation and prediction of in vivo drug metabolism in human populations from in vitro data

  2007influential reference
• Development and Evaluation of a Generic Physiologically Based Pharmacokinetic Model for Children

  2006cited by this paper
• A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics

  2006cited by this paper
• How Modeling and Simulation Have Enhanced Decision Making in New Drug Development

  2005cited by this paper
• COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE ( CHMP ) GUIDELINE ON THE EVALUATION OF THE PHARMACOKINETICS OF MEDICINAL PRODUCTS IN PATIENTS WITH IMPAIRED HEPATIC FUNCTION

  2005cited by this paper
• Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry.

  2004cited by this paper
• Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans.

  2003cited by this paper
• An introduction to the use of physiologically based pharmacokinetic models in risk assessment

  1997cited by this paper
• Physiologically based pharmacokinetics and cancer risk assessment.

  1994cited by this paper
• Integrated risk information system (IRIS)

  1990cited by this paper
• A physiologically based pharmacokinetic model for inhaled carbon tetrachloride.

  1988cited by this paper

• Assessment of the predictive capability of modelling and simulation to determine bioequivalence of inhaled drugs: A systematic review

  2022cites this paper
• The Promise of Long-Acting Antiretroviral Therapies: From Need to Manufacture.

  2019cites this paper
• Development of a Pediatric Physiologically-Based Pharmacokinetic Model of Clindamycin Using Opportunistic Pharmacokinetic Data

  2017cites this paper
• Treating disorders of the neonatal central nervous system: pharmacokinetic and pharmacodynamic considerations with a focus on antiepileptics

  2016cites this paper
• Physiologically Based Pharmacokinetic ( PBPK ) Modeling and Simulation Approaches : A Systematic Review of Published Models , Applications , and Model Verification s

  2015influential citation
• Agent-based modeling: a systematic assessment of use cases and requirements for enhancing pharmaceutical research and development productivity

  2013cites this paper
• Application of Physiologically Based Pharmacokinetic Models in Chemical Risk Assessment

  2012cites this paper
• Physiologically Based Pharmacokinetic (PBPK) Modeling of Metabolic Pathways of Bromochloromethane in Rats

  2012cites this paper
• Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies

  2012cites this paper
• State of the Science: Biologically Based Modeling in Risk Assessment

  2012cites this paper